Can-Fite Secures Australian Patent Allowance Supporting Namodenoson Development and Marketing in Liver and Pancreatic Cancer
Can-Fite BioPharma (NYSE American: CANF) said Australia’s Patent Office allowed Patent Application No. 2021290439 for “Treatment of Advanced Metastatic Cancer.” The company said the patent supports its Namodenoson program, including a Phase 3 pivotal study in advanced hepatocellular carcinoma and a planned Phase 2b with gemcitabine in pancreatic cancer.
How this was made
The 30-second read
Why it matters
The Australian Patent Office’s allowance adds a new layer of IP protection for advanced metastatic cancer, supporting the company’s stated oncology franchise value and long-term market positioning.
Market read
A fresh, company-specific IP milestone that can modestly support valuation sentiment, but it is not a clinical or regulatory catalyst.
What to watch
Australia allowance may have limited immediate revenue impact without clarity on claim scope, exclusivity term, and how it maps to the company’s specific Namodenoson indications and combinations.
Background
Can-Fite is developing Namodenoson, an A3 adenosine receptor small molecule, across Phase 3 (HCC) and Phase 2 (pancreatic cancer, plus MASH enrollment).
Ticker impact
Can-Fite says Australia’s Patent Office allowed a patent application covering treatment of advanced metastatic cancer, strengthening Namodenoson IP.
Likely modest positive bias for CANF, with limited near-term impact unless paired with new clinical/regulatory milestones.
The article discloses a fresh IP event (Australian patent allowance) but provides no new clinical efficacy/safety datapoints or regulatory decisions beyond ongoing trials.
Market effects
Reinforces investor focus on adenosine-receptor oncology assets and the value of expanding global IP coverage.
Improves perceived protection for Namodenoson in the Australian market, potentially aiding future partner discussions there.
Adds to the company’s international IP portfolio narrative, which can support valuation multiples for clinical-stage oncology developers.
Counterpoint
Patent allowance does not guarantee enforceability or commercial success; clinical outcomes and regulatory approvals remain the primary drivers.
Key entities
- companyCan-Fite BioPharma Ltd.
Clinical-stage biotech developing Namodenoson and other oncology/inflammatory candidates.
- drug_candidateNamodenoson
A3 adenosine receptor-targeting small molecule in late-stage and mid-stage oncology programs.
- regulatorAustralian Patent Office
Allowed Patent Application No. 2021290439 for treatment of advanced metastatic cancer.
